Learn More
The objective of this study was to assess the incidence, risk factors, outcome and impact on OS of pericardial effusion (PEF) in a cohort of 156 pediatric SCT recipients. The mean age was 8.15±6.25 years. In all, 74% of the patients had malignant disease and 35% of the patients received autologous stem cell grafts. Twenty-three subjects developed effusion(More)
The outcome of children, adolescents and young adults (CAYA) with poor-risk recurrent/refractory lymphoma is dismal (⩽30%). To overcome this poor prognosis, we designed an approach to maximize an allogeneic graft vs lymphoma effect in the setting of low disease burden. We conducted a multi-center prospective study of myeloablative conditioning (MAC) and(More)
BU and CY (BU/CY; 200 mg/kg) before HLA-matched sibling allo-SCT in children with sickle cell disease (SCD) is associated with ~85% EFS but is limited by the acute and late effects of BU/CY myeloablative conditioning. Alternatives include reduced toxicity but more immunosuppressive conditioning. We investigated in a prospective single institutional study,(More)
OBJECTIVE To investigate the outcomes, survival status, and the prognostic factors of Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis (EBV-HLH) patients. METHODS A retrospective study was carried out to analyze the clinical data of 61 EBV-HLH cases, from January 2008 to July 2014. Prognostic factors were analyzed through COX model (single(More)
Myeloablative regimens are the backbone of hematopoietic SCT (HSCT) and are associated with prolonged periods of gastrointestinal morbidities and compromised gut integrity. While not yet validated for the pediatric or adult HSCT population, serum citrulline levels appear to be an appropriate and accurate measure of morbidities following myeloablative(More)
Myeloablative conditioning (MAC) (full-intensity conditioning) followed by hematopoietic stem cell transplant (HSCT) provides curative therapy for malignant and non-malignant conditions. Reduced toxicity conditioning (RTC) followed by HSCT is efficacious and can reduce the risk of transplant-related morbidity and mortality. Deterioration in long-term(More)
OBJECTIVE A major cause of hemophagocytic lymphohistiocytosis (HLH) is malignant neoplasms of the blood system, among which NK/T cell lymphoma is one of the most common risk factors. Patients with NK/T cell lymphoma hemophagocytic lymphohistiocytosis (NK/T-LAHS) have a worse prognosis and higher mortality. We aimed to explore the factors that affect the(More)
  • 1